Biolimus-Eluting Stents for Primary Percutaneous Coronary Intervention

At 1-year follow-up, biodegradable polymer drug-eluting stents outperformed bare-metal stents in patients with ST-segment-elevation myocardial infarction.

In biolimus-eluting stents (BESs), the drug is released from a biodegradable polymer, which may result in better vessel healing than with durable-polymer stents. In this trial, sponsored in part by the manufacturer, 1161 patients undergoing percutaneous coronary intervention for ST-segment-elevation myocardial infarction were randomized to receive a BES or a bare-metal stent (BMS) identical in appearance. Baseline characteristics were similar between the two groups.

At 1 year, the primary composite endpoint of cardiac death, ischemia-driven target-vessel revascularization, and target-vessel reinfarction occurred in 4.3% of BES recipients and 8.7% of BMS recipients (hazard ratio, 0.49; P=0.004) — a difference driven by revascularization and r…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI